These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 29239900)

  • 21. Programmatic Evaluation of an Algorithm for Intensified Tuberculosis Case Finding and Isoniazid Preventive Therapy for People Living With HIV in Thailand and Vietnam.
    Cowger TL; Thai LH; Duong BD; Danyuttapolchai J; Kittimunkong S; Nhung NV; Nhan DT; Monkongdee P; Thoa CK; Khanh VT; Nateniyom S; Yen NTB; Ngoc DV; Thinh T; Whitehead S; Pevzner ES
    J Acquir Immune Defic Syndr; 2017 Dec; 76(5):512-521. PubMed ID: 29023251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early-phase scale-up of isoniazid preventive therapy for people living with HIV in two districts in Malawi (2017).
    Nabity SA; Gunde LJ; Surie D; Shiraishi RW; Kirking HL; Maida A; Auld AF; Odo M; Jahn A; Nyirenda RK; Oeltmann JE
    PLoS One; 2021; 16(4):e0248115. PubMed ID: 33793577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The protective effect of isoniazid preventive therapy on tuberculosis incidence among HIV positive patients receiving ART in Ethiopian settings: a meta-analysis.
    Geremew D; Endalamaw A; Negash M; Eshetie S; Tessema B
    BMC Infect Dis; 2019 May; 19(1):405. PubMed ID: 31077133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of isoniazid preventive therapy on tuberculosis incidence and associated risk factors among HIV infected adults in Tanzania: a retrospective cohort study.
    Sabasaba A; Mwambi H; Somi G; Ramadhani A; Mahande MJ
    BMC Infect Dis; 2019 Jan; 19(1):62. PubMed ID: 30654753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isoniazid Preventive Therapy for Prevention of Tuberculosis among People Living with HIV in Ethiopia: A Systematic Review of Implementation and Impacts.
    Assefa DG; Zeleke ED; Bekele D; Ejigu DA; Molla W; Woldesenbet TT; Aynalem A; Abebe M; Mebratu A; Manyazewal T
    Int J Environ Res Public Health; 2022 Dec; 20(1):. PubMed ID: 36612942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil.
    Golub JE; Saraceni V; Cavalcante SC; Pacheco AG; Moulton LH; King BS; Efron A; Moore RD; Chaisson RE; Durovni B
    AIDS; 2007 Jul; 21(11):1441-8. PubMed ID: 17589190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence of tuberculosis among PLHIV on antiretroviral therapy who initiated isoniazid preventive therapy: A multi-center retrospective cohort study.
    Kazibwe A; Oryokot B; Mugenyi L; Kagimu D; Oluka AI; Kato D; Ouma S; Tayebwakushaba E; Odoi C; Kakumba K; Opito R; Mafabi CG; Ochwo M; Nkabala R; Tusiimire W; Kateeba Tusiime A; Alinga SB; Miya Y; Etukoit MB; Biraro IA; Kirenga B
    PLoS One; 2022; 17(5):e0266285. PubMed ID: 35576223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study.
    Assebe LF; Reda HL; Wubeneh AD; Lerebo WT; Lambert SM
    BMC Public Health; 2015 Apr; 15():346. PubMed ID: 25886730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IPT in people living with HIV in Myanmar: a five-fold decrease in incidence of TB disease and all-cause mortality.
    Kyaw NTT; Kumar AMV; Kyaw KWY; Satyanarayana S; Magee MJ; Min AC; Moe J; Aung ZZ; Aung TK; Oo MM; Soe KT; Oo HN; Aung ST; Harries AD
    Int J Tuberc Lung Dis; 2019 Mar; 23(3):322-330. PubMed ID: 30871663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy.
    van Griensven J; Choun K; Chim B; Thai S; Lorent N; Lynen L
    Trop Med Int Health; 2015 Dec; 20(12):1823-31. PubMed ID: 26426387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-tuberculosis treatment outcomes in HIV-infected adults exposed to isoniazid preventive therapy in Botswana.
    Sibanda T; Tedla Z; Nyirenda S; Agizew T; Marape M; Miranda AG; Reuter H; Johnson JL; Samandari T
    Int J Tuberc Lung Dis; 2013 Feb; 17(2):178-85. PubMed ID: 23317952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determinants of isoniazid preventive therapy completion among people living with HIV attending care and treatment clinics from 2013 to 2017 in Dar es Salaam Region, Tanzania. A cross-sectional analytical study.
    Robert M; Todd J; Ngowi BJ; Msuya SE; Ramadhani A; Sambu V; Jerry I; Mujuni MR; Mahande MJ; Ngocho JS; Maokola W
    BMC Infect Dis; 2020 Apr; 20(1):276. PubMed ID: 32276618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trend analysis of tuberculosis case notifications with scale-up of antiretroviral therapy and roll-out of isoniazid preventive therapy in Zimbabwe, 2000-2018.
    Takarinda KC; Harries AD; Mutasa-Apollo T; Sandy C; Choto RC; Mabaya S; Mbito C; Timire C
    BMJ Open; 2020 Apr; 10(4):e034721. PubMed ID: 32265241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
    ; Danel C; Moh R; Gabillard D; Badje A; Le Carrou J; Ouassa T; Ouattara E; Anzian A; Ntakpé JB; Minga A; Kouame GM; Bouhoussou F; Emieme A; Kouamé A; Inwoley A; Toni TD; Ahiboh H; Kabran M; Rabe C; Sidibé B; Nzunetu G; Konan R; Gnokoro J; Gouesse P; Messou E; Dohoun L; Kamagate S; Yao A; Amon S; Kouame AB; Koua A; Kouamé E; Ndri Y; Ba-Gomis O; Daligou M; Ackoundzé S; Hawerlander D; Ani A; Dembélé F; Koné F; Guéhi C; Kanga C; Koule S; Séri J; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatounde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Assi R; Bakayoko A; Mahassadi A; Attia A; Oussou A; Mobio M; Bamba D; Koman M; Horo A; Deschamps N; Chenal H; Sassan-Morokro M; Konate S; Aka K; Aoussi E; Journot V; Nchot C; Karcher S; Chaix ML; Rouzioux C; Sow PS; Perronne C; Girard PM; Menan H; Bissagnene E; Kadio A; Ettiegne-Traore V; Moh-Semdé C; Kouame A; Massumbuko JM; Chêne G; Dosso M; Domoua SK; N'Dri-Yoman T; Salamon R; Eholié SP; Anglaret X
    N Engl J Med; 2015 Aug; 373(9):808-22. PubMed ID: 26193126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implementing isoniazid preventive therapy in a tuberculosis treatment-experienced cohort on ART.
    Maharaj B; Gengiah TN; Yende-Zuma N; Gengiah S; Naidoo A; Naidoo K
    Int J Tuberc Lung Dis; 2017 May; 21(5):537-543. PubMed ID: 28399969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data.
    Ross JM; Badje A; Rangaka MX; Walker AS; Shapiro AE; Thomas KK; Anglaret X; Eholie S; Gabillard D; Boulle A; Maartens G; Wilkinson RJ; Ford N; Golub JE; Williams BG; Barnabas RV
    Lancet HIV; 2021 Jan; 8(1):e8-e15. PubMed ID: 33387480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of isoniazid preventive therapy on tuberculosis or death in persons with HIV: a retrospective cohort study.
    Ayele HT; van Mourik MS; Bonten MJ
    BMC Infect Dis; 2015 Aug; 15():334. PubMed ID: 26269094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Initiation and completion rates of isoniazid preventive therapy among people living with HIV in Far-Western Region of Nepal: a retrospective cohort study.
    Dhungana GP; Thekkur P; Chinnakali P; Bhatta U; Pandey B; Zhang WH
    BMJ Open; 2019 May; 9(5):e029058. PubMed ID: 31147370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.
    Tedla Z; Nyirenda S; Peeler C; Agizew T; Sibanda T; Motsamai O; Vernon A; Wells CD; Samandari T
    Am J Respir Crit Care Med; 2010 Jul; 182(2):278-85. PubMed ID: 20378730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isoniazid preventive therapy completion between July-September 2019: A comparison across HIV differentiated service delivery models in Uganda.
    Mugenyi L; Namuwenge PM; Ouma S; Bakashaba B; Nanfuka M; Zech J; Agaba C; Mijumbi Ojok A; Kaliba F; Bossa Kato J; Opito R; Miya Y; Katureebe C; Hirsch-Moverman Y
    PLoS One; 2024; 19(1):e0296239. PubMed ID: 38166009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.